menu
    • menu
    [{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bucindolol Hydrochloride","moa":"Adrenergic beta-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Biopharma \/ JonesTrading Institutional Services"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AB201","moa":"Tissue factor pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"University Medical Center of Johannes Gutenberg University Mainz","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Recombinant Nematode Anticoagulant Protein c2","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARCA Biopharma \/ University Medical Center of Johannes Gutenberg University Mainz","highestDevelopmentStatusID":"9","companyTruncated":"ARCA Biopharma \/ University Medical Center of Johannes Gutenberg University Mainz"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bucindolol Hydrochloride","moa":"Beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Nematode Anticoagulant Protein c2","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ARCA Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Oruka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Oruka Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"ARCA Biopharma \/ Oruka Therapeutics"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Oruka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"","graph1":"Technology","graph2":"Approved","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Oruka Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"ARCA Biopharma \/ Oruka Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by ARCA Biopharma

    Menu

    ARCA Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Oruka Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            ARCA Biopharma Completes Merger with Oruka Therapeutics, Implements Stock Split

                            Details : Through the merger, the company will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.

                            Brand Name : ORKA-001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 29, 2024

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Oruka Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Oruka Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

                            Details : Through the merger, the company will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.

                            Brand Name : ORKA-001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 03, 2024

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Oruka Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Nematode Anticoagulant Protein c2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ARCA Biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

                            Details : This clinical trial used a 1:1:2 randomization between lower dose rNAPc2, higher dose rNAPc2 and standard of care heparin that was delivered in prophylactic doses in 93% of the patients. rNAPc2 patients received three sub-cutaneous (SC) doses.

                            Brand Name : rNAPc2

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 31, 2022

                            Lead Product(s) : Recombinant Nematode Anticoagulant Protein c2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bucindolol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

                            Details : In a GENETIC-AF Phase 2b clinical trial, the prevalence of bradycardia was significantly lower for Gencaro compared to metoprolol. Gencaro, is an investigational, pharmacologically unique beta-blocker for the treatment of atrial fibrillation in heart fai...

                            Brand Name : Gencaro

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 04, 2022

                            Lead Product(s) : Bucindolol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completio...

                            Details : rNAPc2 (AB201) is a small recombinant protein being developed as a potential treatment for COVID-19 and potentially other viral diseases and a potent, selective inhibitor of tissue factor (TF).

                            Brand Name : AB201

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 28, 2021

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completio...

                            Details : Recombinant nematode anticoagulant protein c2 (rNAPc2) is a novel and potent inhibitor of fVIIa/TF that may improve current therapeutic strategies used in COVID-19.

                            Brand Name : AB201

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 28, 2021

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Nematode Anticoagulant Protein c2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : University Medical Center of Johannes Gutenberg University Mainz

                            Deal Size : $1.9 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ARCA Biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement

                            Details : rNAPc2 is a recombinant protein therapeutic being developed by ARCA as a potential treatment for COVID-19 and other severe viral infections. Deal provides exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID-19 and o...

                            Brand Name : rNAPc2

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 07, 2021

                            Lead Product(s) : Recombinant Nematode Anticoagulant Protein c2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : University Medical Center of Johannes Gutenberg University Mainz

                            Deal Size : $1.9 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB201

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ARCA biopharma's AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designat...

                            Details : AB201 is the only novel compound being developed for COVID Associated Coagulopathy. The Company intends to initiate a Phase 2b clinical trial (ASPEN-COVID-19) of AB201 in approximately 100 patients hospitalized with COVID-19 in December 2020.

                            Brand Name : rNAPc2

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 23, 2020

                            Lead Product(s) : AB201

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

                            Details : ARCA anticipates initiating a Phase 2b/3 sequential clinical trial, ASPEN-COVID-19, of AB201 in approximately 100 patients hospitalized with COVID-19 in the fourth quarter of this year, with Phase 2b followed by a contiguous Phase 3 study that is depende...

                            Brand Name : AB201

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 07, 2020

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ARCA Biopharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVI...

                            Details : AB201 is a small recombinant protein and a potent, selective inhibitor of tissue factor, developed as a potential treatment for RNA virus- associated disease, initially focusing on COVID-19.

                            Brand Name : AB201

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 21, 2020

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth